Socio Today
Congenital Heart Disease (CHD), known locally in Indonesia as Penyakit Jantung Bawaan (PJB), remains one of the most significant challenges in pediatric medicine and public health across the archipelago. While the precise etiology of why a specific child is born with a structural defect in the heart often remains a medical mystery, healthcare experts are increasingly pointing toward a set of identifiable and avoidable risk factors that could drastically reduce the incidence of these conditions. According to Dr. Rizky Adriansyah, M.Ked, a prominent pediatric specialist and the Chairman of the Cardiology Coordination Unit of the Indonesian Pediatric Society (IDAI), the focus of the medical community is shifting toward proactive maternal health management to mitigate these risks before and during pregnancy.
Congenital Heart Disease refers to a range of structural problems with the heart that are present at birth. These defects can involve the walls of the heart, the valves, or the arteries and veins near the heart. They can disrupt the normal flow of blood through the heart, causing it to slow down, go in the wrong direction, or be blocked completely. In Indonesia, the burden of CHD is particularly heavy, acting as the second-largest contributor to neonatal mortality—accounting for approximately 17 percent of deaths in the neonatal period, surpassed only by complications related to prematurity.
The Triad of Modern Risk Factors
During a comprehensive webinar hosted by the Indonesian Pediatric Society, Dr. Rizky Adriansyah highlighted that while science cannot always pinpoint a singular "cause" for a specific case of CHD, three primary risk factors have emerged in recent medical literature as critical points of intervention. These factors are not merely incidental; they represent physiological disruptions that occur during the most sensitive stages of fetal development, particularly during the first trimester when the heart begins to take its complex shape.
The first major risk factor is maternal infection, specifically the Rubella virus. Rubella, often referred to as German measles, is a viral infection that, while mild for the mother, can be catastrophic for a developing fetus. When a pregnant woman contracts Rubella, the virus can cross the placental barrier, leading to Congenital Rubella Syndrome (CRS). This syndrome frequently results in multiple birth defects, with heart malformations being among the most common.
The second factor is nutritional: a deficiency in folic acid. Folic acid, or Vitamin B9, is essential for DNA synthesis and repair. It plays a pivotal role in the closure of the neural tube and the proper formation of the cardiac chambers and outflow tracts. In many regions of Indonesia, where nutritional intake may be inconsistent or lacking in fortified grains and leafy greens, folic acid deficiency remains a silent but potent contributor to birth defects.
The third factor involves the consumption of certain medications by the mother during pregnancy. Dr. Rizky specifically pointed to anti-seizure medications (anti-epileptics). While managing maternal health conditions like epilepsy is vital, certain drugs in this category have been linked to an increased risk of cardiac malformations in the fetus. This highlights the necessity for "pre-conception counseling," where women with chronic conditions work with their doctors to switch to safer medication alternatives before becoming pregnant.
Beyond Lifestyle Stereotypes
Historically, public health messaging regarding CHD often focused heavily on maternal lifestyle choices, such as smoking and alcohol consumption. While these are undoubtedly significant risk factors that can lead to a host of developmental issues, Dr. Rizky noted a shift in the clinical observation of cases. "There are many cases where mothers who do not smoke and do not consume alcohol still give birth to children with CHD," he remarked. This observation underscores the complexity of the disease and suggests that environmental factors, genetics, and the aforementioned medical risks (infection and nutrition) play a much larger role than previously emphasized in traditional public health campaigns.
The implication is clear: a "healthy" lifestyle alone is not a guarantee against CHD. It must be paired with specific medical interventions, such as vaccinations and targeted supplementation, to provide the highest level of protection for the unborn child.
The Statistical Reality and the Treatment Gap
The scale of the CHD problem in Indonesia is daunting when viewed through the lens of global and national statistics. According to the World Health Organization (WHO), approximately one out of every 100 newborns worldwide suffers from some form of CHD. Of these, 25 percent are classified as "critical" CHD, meaning they require surgical intervention or catheterization within the first year—and often the first month—of life to survive.
In the Indonesian context, the data from 2017 reveals that CHD is a primary driver of infant mortality. Despite the high prevalence, the capacity of the Indonesian healthcare system to address these cases remains limited. Dr. Rizky Adriansyah revealed a sobering statistic: less than 50 percent of CHD cases in Indonesia are currently being handled or treated effectively.
This massive treatment gap is the result of a multifaceted crisis in the healthcare infrastructure. First, there is the issue of "geographical lottery," where access to specialized pediatric cardiac centers is concentrated in major urban hubs like Jakarta or Surabaya, leaving families in remote provinces with few options. Second, there is a severe shortage of Human Resources (HR), specifically pediatric cardiologists and thoracic surgeons who specialize in neonatal heart repair. Third, the lack of sophisticated diagnostic tools in community health centers (Puskesmas) means many cases are simply never diagnosed until it is too late. Finally, a general lack of public awareness means that parents may not recognize the subtle signs of heart failure in their infants, attributing them instead to less severe ailments.
Innovations in Early Detection and Diagnosis
To combat the high mortality rate associated with CHD, the medical community is advocating for simpler, more accessible diagnostic methods. While echocardiography remains the "gold standard" for diagnosing heart defects, it requires expensive machinery and highly trained specialists to interpret the results.
As a more immediate and cost-effective solution, Dr. Rizky promotes the use of pulse oximetry screening. This non-invasive test measures the oxygen saturation in the blood. By placing sensors on a newborn’s right hand and either foot, healthcare providers can detect "silent" heart defects that may not be apparent through physical examination alone. If the oxygen levels are low or significantly different between the hand and the foot, it serves as a red flag for critical CHD.
Furthermore, the traditional stethoscope remains a vital tool. The presence of a heart "murmur"—an unusual sound heard between heartbeats—can be an early indicator of structural issues. Dr. Rizky emphasizes that if a murmur is detected, medical professionals must immediately prioritize a full cardiac workup.
The clinical symptoms of CHD can sometimes be subtle. One of the most common signs is "failure to thrive," characterized by slow weight gain despite adequate feeding. In critical cases, symptoms may appear within the first 24 to 48 hours of life, or during the first week, often manifesting as cyanosis (a bluish tint to the skin), rapid breathing, or extreme lethargy.
A Call for National Mobilization and Education
Addressing the CHD crisis in Indonesia requires more than just clinical excellence; it requires a national movement toward education and early screening. Dr. Rizky Adriansyah has been a vocal advocate for empowering frontline healthcare workers, such as midwives and general practitioners in rural areas. He noted that the examination for CHD, particularly using oximetry, takes less than five minutes but can be the difference between life and death for a newborn.
To facilitate this education, resources have been made available through digital platforms. The YouTube channel "Sehatkan Jantung Anak Indonesia" (Healthy the Hearts of Indonesian Children) serves as an educational hub for both parents and medical professionals, providing tutorials on how to perform screenings and what symptoms to watch for.
The path forward involves a two-pronged approach: prevention and early intervention. Prevention starts before conception with the Rubella vaccine and continues through pregnancy with proper folic acid intake and medical supervision of drug use. Early intervention relies on a robust screening process for every child born in the country, regardless of their location.
Socio-Economic Implications and the Role of Policy
The implications of untreated CHD extend beyond individual health; they impact the socio-economic fabric of the nation. The cost of cardiac surgery and long-term care for a child with heart defects is substantial, often placing an immense burden on the national health insurance scheme (BPJS Kesehatan). By investing in prevention—such as universal Rubella vaccination and mandatory folic acid fortification in staple foods—the government could potentially save trillions of rupiah in future healthcare costs.
Moreover, children who receive timely treatment for CHD can grow up to lead productive, healthy lives. Conversely, those who are diagnosed late or not at all face a lifetime of disability or premature death, representing a significant loss of human potential for the country.
In conclusion, while the causes of Congenital Heart Disease are complex and not fully understood, the roadmap for reducing its impact in Indonesia is clear. By addressing the identified risk factors of infection, nutrition, and medication, and by closing the diagnostic gap through accessible technology and education, Indonesia can begin to turn the tide against this silent killer. The words of Dr. Rizky Adriansyah serve as a poignant reminder: "If it is already in the baby, it can no longer be prevented; it can only be treated. The window for prevention is during pregnancy." As the nation looks toward a future of improved public health, the protection of its youngest hearts must remain a top priority.
